TrialAntimicrobial agents and chemotherapy2013

Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose study.

Kristi L Berger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.